Journal
AMERICAN JOURNAL OF ROENTGENOLOGY
Volume 207, Issue 2, Pages 266-273Publisher
AMER ROENTGEN RAY SOC
DOI: 10.2214/AJR.16.16181
Keywords
cancer; contrast medium; fluorescence; multimodality imaging; PET
Funding
- NIH from the National Institute of Biomedical Imaging and Bioengineering [4R00EB013904-03]
Ask authors/readers for more resources
OBJECTIVE. The purpose of this article is to summarize advances in PET fluorescence resolution, agent design, and preclinical imaging that make a growing case for clinical PET fluorescence imaging. CONCLUSION. Existing SPECT, PET, fluorescence, and MRI contrast imaging techniques are already deeply integrated into the management of cancer, from initial diagnosis to the observation and management of metastases. Combined positron-emitting fluorescent contrast agents can convey new or substantial benefits that improve on these proven clinical contrast agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available